Literature DB >> 27059986

[Graves' ophthalmopathy].

A Eckstein1, D Dekowski2, D Führer-Sakel3, U Berchner-Pfannschmidt4, J Esser2.   

Abstract

Graves' orbitopathy (GO) is the main extrathyroidal manifestation of Graves' disease and the full clinical picture can impair the quality of life of the patients considerably. Active inflammation can often be effectively treated by intravenous steroids/immunosuppression, however does not lead to full remission, since inflammation rather quickly results in irreversible fibrosis and increase of orbital fat. Very important is the control of risk factors (smoking cessation, good control of thyroid function, selenium supplementation) to prevent progression to severe stages. Treatment should rely on a thorough assessment of activity and severity of GO. Rehabilitative surgery (orbital decompression, squint surgery, eyelid surgery) is needed in many patients to restore function and appearance. Anti-thyroid-stimulating hormone (TSH) receptor antibodies do specifically occur in these patients and correlate to the course of thyroid and eye disease. The levels of these antibodies can be used for treatment decisions at certain time points of the disease.

Entities:  

Keywords:  Graves’ disease; Graves’ orbitopathy; Immunmodulatory therapy; Reconstructive surgical procedures; Thyroid-stimulating hormone receptor

Mesh:

Substances:

Year:  2016        PMID: 27059986     DOI: 10.1007/s00347-016-0239-3

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  31 in total

Review 1.  Relationship between cigarette smoking and Graves' ophthalmopathy.

Authors:  L Hegediüs; T H Brix; P Vestergaard
Journal:  J Endocrinol Invest       Date:  2004-03       Impact factor: 4.256

Review 2.  Treatment modalities for Graves' ophthalmopathy: systematic review and metaanalysis.

Authors:  Hadas Stiebel-Kalish; Eyal Robenshtok; Murat Hasanreisoglu; David Ezrachi; Ilan Shimon; Leonard Leibovici
Journal:  J Clin Endocrinol Metab       Date:  2009-06-02       Impact factor: 5.958

Review 3.  Natural history of thyroid eye disease.

Authors:  P Perros; P Kendall-Taylor
Journal:  Thyroid       Date:  1998-05       Impact factor: 6.568

4.  Psychosocial morbidity of Graves' orbitopathy.

Authors:  G J Kahaly; F Petrak; J Hardt; S Pitz; U T Egle
Journal:  Clin Endocrinol (Oxf)       Date:  2005-10       Impact factor: 3.478

5.  Results of transantral orbital decompression in 428 patients with severe Graves' ophthalmopathy.

Authors:  J A Garrity; V Fatourechi; E J Bergstralh; G B Bartley; C W Beatty; L W DeSanto; C A Gorman
Journal:  Am J Ophthalmol       Date:  1993-11-15       Impact factor: 5.258

Review 6.  Acute thyroid eye disease (TED): principles of medical and surgical management.

Authors:  D H Verity; G E Rose
Journal:  Eye (Lond)       Date:  2013-02-15       Impact factor: 3.775

7.  Measuring disease activity to predict therapeutic outcome in Graves' ophthalmopathy.

Authors:  C B Terwee; M F Prummel; M N Gerding; G J Kahaly; F W Dekker; W M Wiersinga
Journal:  Clin Endocrinol (Oxf)       Date:  2005-02       Impact factor: 3.478

8.  Ciclosporin and prednisone v. prednisone in treatment of Graves' ophthalmopathy: a controlled, randomized and prospective study.

Authors:  G Kahaly; J Schrezenmeir; U Krause; B Schweikert; S Meuer; W Muller; R Dennebaum; J Beyer
Journal:  Eur J Clin Invest       Date:  1986-10       Impact factor: 4.686

9.  [Update on endocrine orbitopathy].

Authors:  A Eckstein; U Berchner-Pfannschmidt; D Führer; J Esser
Journal:  Ophthalmologe       Date:  2013-11       Impact factor: 1.059

Review 10.  [Botulinum toxin treatment for crocodile tears, spastic entropion and for dysthyroid upper eyelid retraction].

Authors:  B Wabbels; M Förl
Journal:  Ophthalmologe       Date:  2007-09       Impact factor: 1.174

View more
  5 in total

1.  Early macular and peripapillary vasculature dropout in active thyroid eye disease.

Authors:  Mansoreh Jamshidian Tehrani; Zahra Mahdizad; Abolfazl Kasaei; Masoud Aghsaei Fard
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-08-23       Impact factor: 3.117

2.  The influence of orbital decompression on objective nasal function in patients with graves' orbitopathy.

Authors:  Kerstin Stähr; Laura Holtmann; Anke Schlüter; Friederike Kaster; Michael Oeverhaus; Stephan Lang; Anja Eckstein; Stefan Mattheis
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-08-30       Impact factor: 2.503

3.  18 F-FDG-PET/MRI in patients with Graves' orbitopathy.

Authors:  Manuel Weber; Cornelius Deuschl; Nikolaos Bechrakis; Lale Umutlu; Gerald Antoch; Anja Eckstein; Ina Binse; Michael Oeverhaus
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-08-18       Impact factor: 3.117

4.  Choroidal Thickness in Thyroid Eye Disease: Comparison With Controls and Application in Diagnosing Non-Inflammatory Active Disease.

Authors:  Tarjani V Dave; Ramya Natarajan; Rakshi Ugandhar Reddy; Anasua G Kapoor; Vivek P Dave
Journal:  Cureus       Date:  2021-11-20

5.  Proposing a surgical algorithm for graduated orbital decompression in patients with Graves' orbitopathy.

Authors:  Anja Eckstein; Stefan Mattheis; Kerstin Stähr; Anke Daser; Michael Oeverhaus; Timon Hussain; Stephan Lang
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-07-21       Impact factor: 3.236

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.